Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. - PE Ratioverified

SLRX

Price:

$0.84

Market Cap:

$3.23M

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with S...[Read more]

Industry

Biotechnology

IPO Date

2015-01-29

Stock Exchange

NASDAQ

Ticker

SLRX

The PE Ratio as of June 2026 (TTM) for Salarius Pharmaceuticals, Inc. (SLRX) is -0.03

According to Salarius Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.03. This represents a change of -98.89% compared to the average of -3.13 of the last 4 quarters.

Salarius Pharmaceuticals, Inc. (SLRX) Historical PE Ratio (quarterly & annually)

How has SLRX PE Ratio performed in the past?

The mean historical PE Ratio of Salarius Pharmaceuticals, Inc. over the last ten years is -12.17. The current -0.03 PE Ratio has changed -71.52% with respect to the historical average. Over the past ten years (40 quarters), SLRX's PE Ratio was at its highest in in the December 2025 quarter at -0.10. The PE Ratio was at its lowest in in the September 2016 quarter at -815.54.

Quarterly (TTM)
Annual

Average

-12.17

Median

-11.54

Minimum

-26.07

Maximum

-0.30

Salarius Pharmaceuticals, Inc. (SLRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Salarius Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 528.84%

Maximum Annual PE Ratio = -0.30

Minimum Annual Increase = -93.60%

Minimum Annual PE Ratio = -26.07

Quarterly (TTM)
Annual
YearPE RatioChange
2025-0.30-92.13%
2024-3.8187.68%
2023-2.0364.51%
2022-1.23-93.60%
2021-19.27-16.73%
2020-23.148.25%
2019-21.38528.84%
2018-3.40-83.85%
2017-21.05-19.29%
2016-26.07-63.70%

Salarius Pharmaceuticals, Inc. (SLRX) Average PE Ratio

How has SLRX PE Ratio performed in the past?

The current PE Ratio of Salarius Pharmaceuticals, Inc. (SLRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.05

5-year avg

-5.33

10-year avg

-12.17

Salarius Pharmaceuticals, Inc. (SLRX) PE Ratio vs. Peers

How is SLRX’s PE Ratio compared to its peers?

Salarius Pharmaceuticals, Inc.’s PE Ratio is less than SciSparc Ltd. (-0.03), greater than Indaptus Therapeutics, Inc. (-0.62), greater than GT Biopharma, Inc. (-0.08), less than Silexion Therapeutics Ltd. (0.06), greater than Avenue Therapeutics, Inc. (-0.61), greater than Revelation Biosciences, Inc. (-0.07), greater than Lipella Pharmaceuticals Inc. (-0.07), greater than Enveric Biosciences, Inc. (-0.05), greater than NKGen Biotech, Inc. Common Stock (-0.12), less than Psyence Biomedical Ltd. (1.77),

Build a custom stock screener for Salarius Pharmaceuticals, Inc. (SLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Salarius Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Salarius Pharmaceuticals, Inc. (SLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Salarius Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Salarius Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the highest PE Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 3-year average PE Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 5-year average PE Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

How does the current PE Ratio for Salarius Pharmaceuticals, Inc. (SLRX) compare to its historical average?